These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29413684)

  • 1. Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.
    Verlingue L; Hollebecque A; Lacroix L; Postel-Vinay S; Varga A; El Dakdouki Y; Baldini C; Balheda R; Gazzah A; Michot JM; Marabelle A; Mir O; Arnedos M; Rouleau E; Solary E; De Baere T; Angevin E; Armand JP; Michiels S; André F; Deutsch E; Scoazec JY; Soria JC; Massard C
    Eur J Cancer; 2018 Mar; 92():1-10. PubMed ID: 29413684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
    Ross JS; Fakih M; Ali SM; Elvin JA; Schrock AB; Suh J; Vergilio JA; Ramkissoon S; Severson E; Daniel S; Fabrizio D; Frampton G; Sun J; Miller VA; Stephens PJ; Gay LM
    Cancer; 2018 Apr; 124(7):1358-1373. PubMed ID: 29338072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.
    Saunus JM; Quinn MC; Patch AM; Pearson JV; Bailey PJ; Nones K; McCart Reed AE; Miller D; Wilson PJ; Al-Ejeh F; Mariasegaram M; Lau Q; Withers T; Jeffree RL; Reid LE; Da Silva L; Matsika A; Niland CM; Cummings MC; Bruxner TJ; Christ AN; Harliwong I; Idrisoglu S; Manning S; Nourse C; Nourbakhsh E; Wani S; Anderson MJ; Fink JL; Holmes O; Kazakoff S; Leonard C; Newell F; Taylor D; Waddell N; Wood S; Xu Q; Kassahn KS; Narayanan V; Taib NA; Teo SH; Chow YP; kConFab ; Jat PS; Brandner S; Flanagan AM; Khanna KK; Chenevix-Trench G; Grimmond SM; Simpson PT; Waddell N; Lakhani SR
    J Pathol; 2015 Nov; 237(3):363-78. PubMed ID: 26172396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics.
    Kiavue N; Cabel L; Melaabi S; Bataillon G; Callens C; Lerebours F; Pierga JY; Bidard FC
    Oncogene; 2020 Jan; 39(3):487-502. PubMed ID: 31519989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
    Hyman DM; Piha-Paul SA; Won H; Rodon J; Saura C; Shapiro GI; Juric D; Quinn DI; Moreno V; Doger B; Mayer IA; Boni V; Calvo E; Loi S; Lockhart AC; Erinjeri JP; Scaltriti M; Ulaner GA; Patel J; Tang J; Beer H; Selcuklu SD; Hanrahan AJ; Bouvier N; Melcer M; Murali R; Schram AM; Smyth LM; Jhaveri K; Li BT; Drilon A; Harding JJ; Iyer G; Taylor BS; Berger MF; Cutler RE; Xu F; Butturini A; Eli LD; Mann G; Farrell C; Lalani AS; Bryce RP; Arteaga CL; Meric-Bernstam F; Baselga J; Solit DB
    Nature; 2018 Feb; 554(7691):189-194. PubMed ID: 29420467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
    Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.
    Choudhury NJ; Campanile A; Antic T; Yap KL; Fitzpatrick CA; Wade JL; Karrison T; Stadler WM; Nakamura Y; O'Donnell PH
    J Clin Oncol; 2016 Jun; 34(18):2165-71. PubMed ID: 27044931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.
    Baccarani M; Soverini S; De Benedittis C
    Am Soc Clin Oncol Educ Book; 2014; ():167-75. PubMed ID: 24857074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value.
    Jiang X; Pissaloux D; De La Fouchardiere C; Desseigne F; Wang Q; Attignon V; Fondrevelle ME; De La Fouchardiere A; Perol M; Cassier P; Seigne C; Perol D; Ray-Coquard I; Meeus P; Fayette J; Flechon A; Le Cesne A; Penel N; Tredan O; Blay JY
    Oncotarget; 2015 Sep; 6(28):26388-99. PubMed ID: 26317543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance.
    Chen Y; Lu A; Hu Z; Li J; Lu J
    Cancer Lett; 2024 Sep; 599():217146. PubMed ID: 39098760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The HER3/ERBB3 receptor: the dark side of the ERBB planet].
    Larbouret C; Gaborit N; Poul MA; Pèlegrin A; Chardès T
    Med Sci (Paris); 2015 May; 31(5):465-8. PubMed ID: 26059291
    [No Abstract]   [Full Text] [Related]  

  • 16. PIK3CA mutations in advanced cancers: characteristics and outcomes.
    Janku F; Wheler JJ; Naing A; Stepanek VM; Falchook GS; Fu S; Garrido-Laguna I; Tsimberidou AM; Piha-Paul SA; Moulder SL; Lee JJ; Luthra R; Hong DS; Kurzrock R
    Oncotarget; 2012 Dec; 3(12):1566-75. PubMed ID: 23248156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.
    Kim HS; Kim SM; Kim H; Pyo KH; Sun JM; Ahn MJ; Park K; Keam B; Kwon NJ; Yun HJ; Kim HG; Chung IJ; Lee JS; Lee KH; Kim DJ; Lee CG; Hur J; Chung H; Park JC; Shin SK; Lee SK; Kim HR; Moon YW; Lee YC; Kim JH; Paik S; Cho BC
    Oncotarget; 2015 Dec; 6(42):44971-84. PubMed ID: 26462025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
    Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
    Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
    JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.